The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...

The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for ...

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

The tablet formulation can either be swallowed whole or dispersed in a teaspoon of filtered (non-chlorinated) water.

The first prenatal therapy for spinal muscular atrophy (SMA) showed promising results, a case report indicated. More than 2 ...

Evrysdi is the only non-invasive disease-modifying ... Calif., February 12, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and ...

The U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of Evrysdi (risdiplam), an approved oral ...

Basel: Roche, announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an ...

Roche, announced that the US Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi (risdiplam) tablet for people living with spinal muscular atrophy (SMA).

FDA Approves Tablet Version of Roche’s SMA Drug Evrysdi The FDA granted approval to a tablet (5 mg) formulation of Roche’s SMA drug Evrysdi, which is currently available as an oral solution.